Covered recipient · General Payments record
ZHEN HOU
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
General Payments · PY2018–2023
$2,022.82
- Reported across 105 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2023 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $198.19 | 10 |
By paying entity
PY2023 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $62.94 | 3 |
| Genentech USA, Inc. | $22.93 | 1 |
| ABBVIE INC. | $22.33 | 1 |
| Lilly USA, LLC | $21.96 | 1 |
| Amgen Inc. | $20.63 | 1 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $18.81 | 1 |
| Celgene Corporation | $15.14 | 1 |
| Sumitomo Pharma America, Inc. | $13.45 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2023 (10)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $22.33 | 05/18/2023 | Food and Beverage | Undisputed | 01/23/2026 | 997504133 | CMS |
| Amgen Inc. | $20.63 | 04/13/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1020700967 | CMS |
| Celgene Corporation | $15.14 | 01/19/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1016060397 | CMS |
| E.R. Squibb & Sons, L.L.C. | $24.81 | 01/12/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1016060389 | CMS |
| E.R. Squibb & Sons, L.L.C. | $23.73 | 01/12/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1016060393 | CMS |
| E.R. Squibb & Sons, L.L.C. | $14.40 | 04/27/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1016060505 | CMS |
| Genentech USA, Inc. | $22.93 | 05/11/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1040606035 | CMS |
| Lilly USA, LLC | $21.96 | 05/04/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1032655147 | CMS |
| Novartis Pharmaceuticals Corporation | $18.81 | 03/30/2023 | Food and Beverage | Undisputed | 01/23/2026 | 992128719 | CMS |
| Sumitomo Pharma America, Inc. | $13.45 | 02/11/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1030904689 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023
- Generated from
- OP_DTL_GNRL_PGYR2023_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.